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Background: Acute myeloid leukemia with complex karyotype (CK-AML) is a distinct biological entity associated
with a very poor outcome. Since complex karyotypes frequently contain deletions of the chromosomal region
12p13 encompassing the tumor suppressor genes ETV6 and CDKN1B, we aimed to unravel their modes of
inactivation in CK-AML.
Results: To decipher deletions, mutations and methylation of ETV6 and CDKN1B, arrayCGH, SNP arrays, direct
sequencing of all coding exons and pyrosequencing of the 5′UTR CpG islands of ETV6 and CDKN1B were
performed. In total, 39 of 79 patients (49%) showed monoallelic deletions of 12p13 according to karyotypic data
and 20 of 43 patients (47%) according to genomic profiling. Genomic profiling led to the minimal deleted region
covering the 3′-UTR of ETV6 and CDKN1B. Direct sequencing revealed one novel monoallelic frameshift mutation
in ETV6 while no mutations in CDKN1B were identified. Furthermore, methylation levels of ETV6 and CDKN1B did
not indicate transcriptional silencing of any of these genes. ETV6 and CDKN1B had reduced expression levels in
CK-AML patients with deletion in 12p13 as compared to CK-AML without deletion in 12p13, while the other
genes (BCL2L14, LRP6, DUSP16 and GPRC5D) located within the minimal deleted region in 12p13 had very low or
missing expression in CK-AML irrespective of their copy number status.
Conclusions: ETV6 and CDKN1B are mainly affected by small monoallelic deletions, whereas mutations and
hypermethylation play a minor role in CK-AML. Reduced gene dosage led to reduced gene expression levels,
pointing to haploinsufficiency as the relevant mechanism of inactivation of ETV6 and CDKN1B in CK-AML.
Keywords: Acute myeloid leukemia (AML), Complex karyotype, Haploinsufficiency, ETV6, CDKN1B, ArrayCGH,
Methylation, Gene expressionBackground
Acute myeloid leukemia (AML) is a hematopoietic
malignancy of clonal myeloid progenitor cells arrested at
an immature differentiation stage. There is substantial
phenotypic and genetic heterogeneity due to the acquisi-
tion of different genetic and/or epigenetic alterations in
leukemia-initiating cells [1]. Acute myeloid leukemia
with complex karyotype (CK-AML) is a distinct biological* Correspondence: Steinemann.Doris@mh-hannover.de
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three independent chromosome aberrations, excluding
t(8;21), inv(16)/t(16;16), and t(15;17) and is associated
with a very poor outcome [2,3]. More than 150 genes have
been shown to be differentially expressed in CK-AML
compared to AML with normal karyotype, including
several genes located on 5q and 7q as well as genes
involved in DNA repair, chromosome segregation, and
within the actin cytoskeleton [4]. CK-AML often contains
deletions of 5q, 7q, and 17p and shows high incidence of
somatic alterations of TP53 [5-7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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types frequently contain deletions of the chromosomal
region 12p13 [8-10]. The reported minimal deleted
region of 12p13 spans two putative tumor suppressor
genes, ETV6 and CDKN1B [11-13]. For both genes, hap-
loinsufficiency as the underlying mechanism was previ-
ously suggested, as they are located within the minimal
deleted region and inactivation of the second allele is
rarely seen [12,14,15]. Furthermore, haploinsufficiency of
CDKN1B is strongly implicated in numerous cancer
types, the vast majority of lymphatic origin [16,17].
ETV6 (ets translocation variant gene 6), a member of
the ETS transcription factor family, shows several proper-
ties of a putative tumor suppressor gene like induction of
G1 arrest and blocking of Ras-induced transformation
[18], induction of apoptosis [19], and activation of TP53
dependent pathways [20]. CDKN1B encodes the p27CD
KN1B protein which belongs to the CIP/KIP class of cyc-
lin dependent kinase inhibitors and inactivates the cyclin
E/CDK2 complex via binding of CDKN1B to cyclin
E/CDK2 [21]. CDKN1B is hence an important negative
regulator of the cell cycle.
In this study, we aimed to investigate whether and
how ETV6 and CDKN1B are inactivated by (small) dele-
tions, mutations or DNA methylation in the specific
subgroup of CK-AML.
Results
Standard karyotyping and genomic profiling of 12p13
We extensively characterized a cohort of 79 patients
with CK-AML. Thirty-nine of them (49%) showed a loss
of 12p13 according to karyotyping (Additional file 1:
Table S1). This included deletions of 12p13 due to inter-
stitial deletions, unbalanced translocations, and mono-
somy 12. A monosomy 12 was observed in 13 patients, a
deletion of 12p13 either by interstitial or terminal deletion
or by additive chromosomal material in 21 patients and a
dicentric or derivative chromosome with loss of 12p in five
patients. The frequency of cytogenetically detectable -5/
5q-, -7/7q- or -17/17p- did not differ in the groups of
CK-AML with and without 12p13 deletion (analyzed with
Fisher’s exact test, p-values: -5/5q- 0.81, -7/7q- 0.17, -17/
17p- 0.36).
In 43 patients, DNA was available for genomic profiling
[array comparative genomic hybridization (arrayCGH) or
single-nucleotide polymorphism (SNP) arrays] to deter-
mine the allelic status of 12p13 and delineate the break-
points of 12p more closely. In 26 of these patients we used
arrayCGH methods (244 k array, 2.8 k array and 8.0 k
array), five patients were analyzed by using the SNP 250 k
array and 12 patients were analyzed by using the SNP 6.0
array. In summary, in 20 of 43 patients (47%), losses of
12p13 could be identified by genomic profiling en-
compassing the ETV6 and CDKN1B genes. With thisapproach, three patients were newly detected to carry a
deletion in 12p13 (#61, #64, #77), however in six patients
(#13, #22, #36, #41, #69, #70) a loss of 12p13 according to
karyotyping was not confirmed (Additional file 1: Table
S1). Small interstitial deletions within the chromosomal
region 12p13 were identified in 13 of 43 patients with CK-
AML analyzed by arrayCGH and SNP arrays. The distal
breakpoints mapped within a region of 30 kb directly 5′ to
ETV6, except in one patient (#48), where the first deleted
probe was localized in the 3′UTR of ETV6. The proximal
breakpoints were all downstream of GPRC5D (G-protein-
coupled receptor, family C, group 5). The minimal deleted
region in our cohort spanned 1.43 Mb and included
CDKN1B and the 3′UTR of ETV6 (Figure 1).
12p13 deletion breakpoints
A graphic overview of the 12p13 deletion breakpoints
including or excluding ETV6 and CDKN1B from differ-
ent studies also comprising our data is shown in Figure 2.
Most of these studies refer to (CK-) AML or contain a
large number of patients with AML. Some studies re-
ported minimal deleted regions containing either ETV6 or
CDKN1B. However, in the majority of studies, the min-
imal deleted region covered both ETV6 and CDKN1B.
Mutation analyses of ETV6, CDKN1B and TP53
To further determine the modes of inactivation of ETV6
[NM_001987] and CDKN1B [NM_004064], we per-
formed mutation analyses of all coding exons of ETV6
in 56 patients and of CDKN1B in 67 patients with and
without 12p13 deletions for which DNA was available
(Additional file 1: Table S1). In our cohort of CK-AML,
no CDKN1B mutations were identified. However, in
ETV6 we found a distinct and novel heterozygous frame-
shift mutation of exon 4, c.391dupT, p.(Ser131Phef-
sTer23) in one patient (#21) (Figure 3). This frameshift
mutation lies within the N-terminal homodimerization
domain and theoretically would disturb homodime-
rization, thus leading to a complete loss of the DNA-
binding ETS domain. A deleterious effect was confirmed
by using the platform PROVEAN for non-synonymous
or indel variants and prediction of functional effects
(http://provean.jcvi.org/index.php) [22]. The mutation
was detected at the time point of relapse. Importantly, in
the first diagnostic sample of this patient still showing a
normal karyotype, the ETV6 mutation was present, indi-
cating that this mutation emerged early in the course of
the disease. In the following samples during the course
of the disease, a complex karyotype with several bal-
anced translocations and a terminal deletion of 14q was
detected (Additional file 1: Table S1). By means of
arrayCGH, no gains or losses in the region of the ETV6
gene were evident. Notably, no TP53, FLT3 nor CEBPA
mutations (data not shown) and no typical cytogenetic
Figure 1 Interstitial 12p13 deletions. ArrayCGH results (244 k, Agilent) showing interstitial 12p13 deletions in six patients. The genomic profiles
are zoomed in to the minimal deleted region covering ETV6 at the telomeric site and CDKN1B at the centromeric site. Deleted regions are
highlighted in gray. Next to the breakpoint region given in Mb, the size of the deletion is shown. The ETV6 gene is orientated in 5′-3′ direction.
Mean log ratios of the deletions correlate with the clone size according to karyotyping.
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(17p) were present in this patient. However an NPM1
mutation (c.860_863dup, p.(Trp288CysfsTer12)) was
identified (data not shown).
To determine the frequency of TP53 mutations in the
subgroup with and without 12p13 deletions, we per-
formed mutation analysis of all coding exons of TP53 in
all 79 patients. In 44 of 79 patients (56%), TP53 muta-
tions were identified (see Additional file 2: Table S2).
The frequency of 12p13 alterations was similar in pa-
tients with and without a monoallelic or biallelic inacti-
vation of TP53 (45.5% versus 45.7%, p = 0.99).Methylation analyses of ETV6 and CDKN1B
To determine the methylation status of ETV6 and
CDKN1B, quantitative methylation analysis of the 5′UTRs
of both genes was performed by pyrosequencing. We ex-
amined 23 single CpG sites within the ETV6 5′UTR CpG
island and 22 single CpG sites within the CDKN1B 5′
UTR CpG island in 55 patients (27 with 12p13 deletions,
28 without 12p13 deletions). The mean methylation levels
of ETV6 and CDKN1B ranged from 0% to 1.43% and
0.09% to 1.77%, respectively (Figure 4, Additional file 1:
Table S1). These results did not exceed the cut-off levels
of 5% indicative for increased methylation. Neither did the
Figure 2 12p minimal deleted regions from different studies. The ideogram of the chromosome arm 12p is shown on the left. The region
from 11.8 Mb to 12.9 Mb is zoomed in to the genes ETV6, BCL2L14, LRP6, DUSP16, and CDKN1B given as black bars. The red bars to the right of the
genes indicate the minimal deleted regions as described in the different studies shown below. Most of these studies refer to (CK-) AML or contain a
large number of patients with AML. The red bar on the right displays the minimal deleted region identified in this study. A dashed line indicates
that the border of the deletion is not exactly determined or exceeds the selected chromosomal region.
Figure 3 ETV6 mutation. Heterozygous frame shift mutation in exon 4, c.391dupT, p.(Ser131PhefsTer23), leading to truncated protein due to a
newly generated stop codon (patient #21).
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Figure 4 Methylation analyses of ETV6 and CDKN1B. a1/a2: Schematic view of the ETV6/CDKN1B-CpG islands: each vertical bar represents a
single CpG site. Arrows indicate the start of the non-coding exon 1 and the start codon. The positions of the PCR product and the product used
for pyrosequencing are indicated below as horizontal bars. b1/b2: A representative pyrogram determining the nucleotide sequence within the
CpG island of ETV6/CDKN1B. The sequence in the upper part of the pyrogram contains a Y at positions under investigation, the sequence below
indicates the injected bases during pyrosequencing. Highlighted areas in the pyrogram indicate variable CpG positions (light gray). The methylation
level of each CpG site is indicated in blue boxes on top of the pyrogram. c1/c2: Mean methylation levels of the 23 CpG sites in the 5′UTR of ETV6
and the 22 CpG sites in the 5′UTR of CDKN1B of all patients analyzed are shown as a percentage. The standard deviation was determined using
the Kruskal-Wallis test.
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ceed the cut-off level. In summary, no evidence of in-
creased methylation of the 5′UTR of either gene was
found.
Expression profiling of the genes within the minimal
deleted region
As we showed that gene dosages of ETV6 and CDKN1B
were reduced to half the normal level in CK-AML sam-
ples with 12p13 deletion, we were interested to deter-
mine whether this is reflected on the transcriptional
level. Therefore, we first evaluated the gene dosage effect
based on our previously published gene expression pro-
filing [23,24]. Expression and genomic data were avail-
able for four of our own patients with CK-AML and
deletion in 12p13 and for 28 cases without deletion in
12p13. The four CK-AML patients with deletion in
12p13 showed a significantly lower expression level for
the deleted genes than CK-AML without deletion in
12p13 (p < 0.001, unpaired t-test, Figure 5A). Within thefour cases with 12p13 deletion we compared the expres-
sion level of the genes located in the critical region with
those on chromosome 12 outside the deleted region and
found a lower expression level for the deleted genes
(Figure 5B).
In addition, we screened the publicly available data of
The Cancer Genome Atlas (TCGA, http://cancergenome.
nih.gov/) for CK-AML patients with and without deletion
in 12p13. We compared eight cases of CK-AML with
deletion in 12p13 and eight cases of CK-AML without
deletion in 12p13. ETV6 and CDKN1B are expressed in
CK-AML with and without deletion in 12p13 (ETV6/
del12p: 37.68 ± 12.95 RPKM, ETV6/no del12p: 71.63 ±
34.43 RPKM; CDKN1B/del12p: 15.19 ± 4.06 RPKM,
CDKN1B/no del12p: 24.73 ± 5.86 RPKM). Notably, the
expression level of ETV6 and CDKN1B decreased signifi-
cantly by 0.53-fold (p < 0.03) and 0.62-fold (p < 0.003),
respectively, in cases with 12p13 deletions compared to
those without 12p13 deletions. The other candidate genes
located within the minimal deleted region (BCL2L14,
Figure 5 12p13 deletion-associated gene dosage effect. A: Comparison of CK-AML with (n = 4) and without 12p13 deletion (n = 28). The box
plot shows the expression values for the genes located in the critical 12p region comprising the following genes: ETV6, BCL2L14, LRP6, DUSP16,
CDKN1B and GPRC5D (normalized log2 transformed gene expression values). Cases with a 12p13 deletion show a significantly lower expression
level for the deleted genes (p < 0.001, unpaired t-test). B: Comparison of the clones located within the critical region and clones located in
unaltered chromosome 12 regions shows a significantly lower expression for the 12p critical region clones in AML cases with a 12p13 deletion
(p = 0.041, ANOVA one-way analysis of variance). C: Comparison of CK-AML cases with (n = 8) and without 12p13 deletion (n = 8). The box plot
shows the RPKM values of RNAseq data representing the expression level of the genes ETV6, BCL2L14, LRP6, DUSP16, CDKN1B and GPRC5D. Cases
with a 12p13 deletion show a significantly lower expression level for ETV6 (p < 0.03, unpaired t-test) and CDKN1B (p < 0.003, unpaired t-test).
BCL2L14, LRP6, DUSP16 and GPRC5D show no or very low expression levels. All data represented here were obtained from the TCGA
network (http://cancergenome.nih.gov).
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pression levels irrespective of their copy number status
(0.13 – 3.72 RPKM) (see Figure 5C).
Discussion
12p13 deletions are common in a broad spectrum of
hematological malignancies, notably in myelodysplastic
syndrome (MDS) with monosomy 7 [25] and CK-AML
[8-10]. ETV6 and CDKN1B are the candidate tumor
suppressor genes within the region 12p13 [12,13]. Other
candidate genes within the minimal deleted region like
BCL2L14, LRP6, DUSP16 and GPRC5D may also play a
role in tumorigenesis and leukemogenesis.
However, we now demonstrate according to the ex-
pression data provided by TCGA in confirmation of datapublished by Haferlach et al, that these genes do not
show any expression or very low expression in blood or
bone marrow cells of AML patients [26]. Likewise, using
the platform HemaExplorer (http://servers.binf.ku.dk/
hemaexplorer/), they show a low expression in normal
hematopoietic stem and progenitor cells, compared to the
expression level of ETV6 (5- to 40-fold higher) and
CDKN1B (3- to 20-fold higher) in these cells [26]. It seems
unlikely that they play a major role in leukemogenesis (see
Figure 5C). Recent data suggest that the function of some
tumor suppressor genes can be disrupted solely by
haploinsufficiency leading to reduced gene dosage which
might be sufficient to contribute to tumorigenesis
[27-29]. Popular examples are TP53, PTEN, NPM1, NF1
and RPS14 [27,29]. Likewise, for the genes APC, ATM,
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tumorigenesis [28]. Haploinsufficiency of CDKN1B is
strongly implicated in numerous cancer types, the vast
majority of lymphatic origin [16,17]. CDKN1B heterozy-
gous mice are predisposed to tumors in multiple tissues
[30]. ETV6 and CDKN1B are known to be inactivated
mostly by monoallelic deletions. Yet, the mode of inacti-
vation has not been investigated in detail in CK-AML
with a high frequency of 12p13 deletions.
In our study, 12p13 deletions, mostly small interstitial
deletions, were present in nearly half (49%) of the ana-
lyzed CK-AML patients according to karyotype. In 20 of
43 patients (47%), losses of 12p13 could be identified by
genomic profiling, of those 13 small interstitial deletions
(see Additional file 1: Table S1). The high frequency may
be explained by high-resolution arrays used in this study.
In previous studies based on karyotyping or SNP arrays
of lower resolution, the frequency of 12p13 deletions in
CK-AML was 27% [31] and 18% [10], respectively. How-
ever, it cannot be excluded that the rather high fre-
quency in our study is due to the relatively small size of
our cohort. The minimal deleted region in our cohort
spanned 1.43 Mb and included CDKN1B and the 3′UTR
of ETV6 (see Figure 1). In one patient (#48) the distal
breakpoint is located within a region between exon 8
and the 3′UTR of the ETV6 gene. As the end of the
ETS DNA-binding domain and the highly conserved
polyadenylation signal lay within the deleted region and
differential polyadenylation of the 3′UTR of ETV6 plays
a major role in posttranscriptional modification [32], we
assume that ETV6 is contained in the minimal deleted
region.
ETV6 and CDKN1B mutations have never been inves-
tigated specifically in CK-AML. Somatic ETV6 muta-
tions are rare events in newly diagnosed AML [33],
AML-M0 [34] and MDS [35]. We detected one hete-
rozygous frameshift mutation among 56 patients (see
Figure 3, Additional file 1: Table S1). Our results thereby
confirm the low rate of ETV6 mutations in the distinct
subgroup of CK-AML. The detected frameshift mutation
lies within the N-terminal homodimerization domain
leading to a complete loss of the DNA-binding ETS do-
main. The vast majority of all reported ETV6 mutations
results in inactivation of one ETV6 allele which is con-
sistent with haploinsufficiency as the underlying mechan-
ism. There was no typical driver alteration like TP53 or
FLT3 mutations and no typical cytogenetic aberrations of
CK-AML like del(5q), -7/del(7q), or del(17p) present in
this patient, which could provide a proliferative advan-
tage or even initiate leukemogenesis. This might
strengthen the role of this ETV6 mutation as a driver ra-
ther than a passenger mutation. Unfortunately, no fibro-
blast DNA was available to prove whether the ETV6
mutation was of germline origin. However, this seems tobe unlikely as ETV6 is a critical regulator in the survival of
multiple cell types during early embryonic development
and ETV6 knockout mice are embryonically lethal [36].
According to the literature, CDKN1B mutations have
been previously reported in childhood leukemia [37] and
rarely in T-cell prolymphocytic leukemia [16] as well as
in adult T-cell leukemia [38]. We did not identify a
mutation in the CDKN1B gene in our analyzed patient
cohort (see Additional file 1: Table S1).
As expected, in more than half of the analyzed pa-
tients, TP53 mutations were detected (see Additional file
2: Table S2). However, the frequency of 12p13 deletions
did not differ between patients with and without a
monoallelic or biallelic alteration of TP53 (45.5% versus
45.7%, p = 0.99).
One mechanism of haploinsufficiency is increased
methylation leading to reduced gene dosage due to tran-
scriptional silencing. For ETV6, increased methylation
was suggested as a possible mechanism since decreased
ETV6 protein expression was reported in AML patients
[33]. Hypermethylation of CDKN1B was excluded in not
further defined AML and MDS, but found in the
lymphoblast-like cell line Raji [39]. We demonstrate here
that the CpG islands within the ETV6 and CDKN1B 5′
UTRs are not hypermethylated in CK-AML (see Figure 4).
To our knowledge, this is the first report that excludes 5′
UTR methylation leading to ETV6 and CDKN1B inacti-
vation in CK-AML and supports haploinsufficiency by
heterozygous deletions as mode of inactivation.
We show by reanalysis of our previously published
gene expression profiling [23,24] of patients with CK-
AML and deletion in 12p13 a significantly lower expres-
sion level for the deleted genes (p < 0.001) compared to
a group of CK-AML patients without 12p13 alteration
(see Figure 5A + B). Furthermore, we screened the pub-
licly available data of TCGA and demonstrate that the
other candidate genes located within the minimal de-
leted region (BCL2L14, LRP6, DUSP16 and GPRC5D)
show no or very low expression levels irrespective of
their copy number. In contrast, ETV6 and CDKN1B are
expressed in CK-AML and their expression levels sig-
nificantly decreased in cases with 12p13 deletions (see
Figure 5C). Thus, ETV6 and CDKN1B are the sole genes
within the minimal deleted region with expression levels
reduced to approximately half. These data strongly sup-
port our hypothesis that haploinsufficiency is the under-
lying mechanism of inactivation of ETV6 and CDKN1B.
Conclusion
In summary, we demonstrate that the putative tumor
suppressor genes ETV6 and CDKN1B are frequently
inactivated by loss of one copy, most frequently by small
deletions of 12p13, in CK-AML. The expression level of
ETV6 and CDKN1B is significantly decreased in cases
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date genes within the minimal deleted region do not show
any or very low expression irrespective of their copy num-
ber status. Mutations and hypermethylation as mode of
inactivation were largely excluded. It is possible that the
genomic complexity leads to acquisition of the deletion
in 12p13. Future studies investigating clonal evolution
should clarify, whether haploinsufficiency of both genes
may cooperate early in the process of leukemic trans-
formation by disordering key processes of differentiation
and proliferation and whether they may also play a
critical role in the induction of chromosomal instability




79 patients with CK-AML were analyzed (see Additional
file 1: Table S1). Complex karyotype was defined by the
presence of at least three chromosomal abnormalities in
the absence of the prognostically favorable t(8;21)(q22;
q22), inv(16)(p13q22) or t(16;16)(p13;q22) and t(15;17)
(q22;q12). The diagnosis of AML was made according to
the French-American-British Cooperative Group criteria.
The karyotypes were described according to the Inter-
national System for Human Cytogenetic Nomenclature
(ISCN) (2013) [40]. DNA for analysis was extracted
from bone marrow or peripheral blood-derived cell pel-
lets stored at -196°C in liquid nitrogen and from metha-
nol/acetic acid fixed cells stored at -80°C, using the
Qiagen QIAamp® DNA Micro/Midi Kit (Qiagen, Hilden,
Germany).
All patients signed informed consent forms, and the pro-
ject was approved by the Ethics Committee of Hannover
Medical School (approval no. 2899 of 20.06.2011). The
research has been conducted in compliance with the
Helsinki declaration.
Array-based genomic profiling
ArrayCGH using the 2.8 k and/or the 8.0 k platform and
SNP analyses using Affymetrix GeneChip Human Map-
ping 250 K Array (Affymetrix, Santa Clara, California)
and/or Genome-Wide Human SNP 6.0 Array (Affyme-
trix, Santa Clara, California) were performed as previ-
ously described by Rücker et al [41]. Results obtained
from BAC/PAC arrayCGH are given in Additional file 3:
Table S3. In brief, cut-off levels for gains and losses were
determined for each individual experiment. After com-
puting the ratios from dye-swap hybridization and sub-
sequent normalization, an individual set of balanced
clones for each experiment was used to calculate the
mean and standard deviations. The cut-off levels were
defined as mean plus/minus three times the standard de-
viation. Frequently affected regions recently detected ascopy number polymorphisms (5q11, 7q22, 7q35, 14q32,
and 15q11) were excluded from data analysis.
For arrayCGH using the Agilent Human Genome
Microarray Kit 244A (Agilent Technologies, Waldbronn,
Germany), a high resolution 60-mer oligonucleotide-
based microarray, the procedures for DNA labeling,
hybridization and washing were performed according to
the manufacturer’s instructions (protocol version 6.1.)
with some modifications as previously described by
Praulich et al [42]. The slides were scanned on an
Agilent Microarray Scanner and captured images were an-
alyzed with Feature Extraction Software (v.10.7) (Agilent
Technologies, Waldbronn, Germany). Data imaging and
analysis were performed by the Agilent CGH Analytics
software (v.5.0.14) with hg18 and Aberration Detection
Method 2 (ADM-2) analysis algorithms set to specified
thresholds and filter settings. All raw data from Agilent
and Affymetrix are available under GEO (Gene expression
omnibus, http://www.ncbi.nlm.nih.gov/geo/). Aberration
summaries are archived under GSE55535. GEO accession
numbers are given in Additional file 4: Table S4.
Direct sequencing
Exons 1-8 of ETV6 (ENSG00000139083), exons 1-2 of
CDKN1B (ENSG00000111276), and exons 2-11 of TP53
(ENSG00000141510) were PCR-amplified from genomic
DNA using FastStart Taq DNA Polymerase (Roche,
Mannheim, Germany). After purification with the mag-
netic bead-based CleanSEQ® system (Beckman Coulter,
Krefeld, Germany), PCR fragments were sequenced in
both directions using the GenomeLab™ DTCS Quick
Start Kit and CEQTM 8000 Genetic Analysis System
(Beckman Coulter, Krefeld, Germany). Cloning of PCR
products was performed in patients with complex muta-
tions to describe the mutations properly using the TOPO
TA Cloning® Kit (Invitrogen, Karlsruhe, Germany). All
mutations were described according to the nomenclature
for the description of sequence variations of the Human
Genome Variation Society (HGVS, http://www.hgvs.org/).
Pyrosequencing
CpG islands were identified using CpG island searcher
(http://cpgislands.usc.edu). We used the following set-
tings: a G + C content of at least 55% GC, an observed
CpG/expected CpG in excess of 0.65, and a minimum
length of 500 bp. The pyrosequenced regions were also
selected in the context of primer design, optimal PCR
conditions and stringency.
Sodium bisulfite treatment of genomic DNA was per-
formed using the EZ DNA Methylation Direct Kit™
(Zymo Research, Freiburg, Germany). Fragments for py-
rosequencing were generated by PCR using the FastStart
Taq™ DNA Polymerase Kit (Roche, Basel, Switzerland)
with the following protocol: 10pmol of forward and
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and 0.78 units of FastStart Taq™ DNA Polymerase as
well as different amounts of dNTPs and MgCl2. Cycle
conditions were as follows: for fragment ETV6 denatur-
ation at 97°C for 7 min, touchdown for 10 cycles includ-
ing denaturation at 96°C for 30 s, annealing at 58°C for
30 seconds (which was decreased by 0.5°C in each cycle)
and extension at 72°C for 1 min, followed by 25 cycles at
96°C for 30 s, annealing at 53°C for 30 s and 72°C for
1 min, finished with 72°C for 7 min; for fragment
CDKN1B denaturation at 97°C for 7 min, touchdown for
10 cycles including denaturation at 96°C for 30 s, anneal-
ing at 53°C for 30 seconds (which was decreased by 0.5°C
in each cycle) and extension at 72°C for 1 min, followed
by 25 cycles at 96°C for 30 s, annealing at 48°C for 30 s
and 72°C for 1 min, finished with 72°C for 7 min. Primer





For purification of biotinylated fragments, 5 to 13 μL
of PCR products were added to a mixture consisting of
3 μL Streptavidin Sepharose HP™ Beads (Amersham Bio-
sciences, Freiburg, Germany) and 47 μL binding buffer
(Qiagen, Hilden, Germany). Single-stranded fragments
were purified using the Vacuum Prep Tool™ (Qiagen,
Hilden, Germany). Sepharose beads with the single-
stranded templates attached were added to a PSQ 96
Plate Low™ (Qiagen, Hilden, Germany) containing a mix
of 11 mL annealing buffer (Qiagen, Hilden, Germany)
and 800 nmmol/L of the corresponding sequencing
primers (Metabion, Martinsried, Germany) with following
sequences: fragETV6-seq: 5′-GATTTG TAGATTT-3′;
fragCDKN1B-seq: 5′-GATTAGTTAATTTTT-3′.
Pyrosequencing was performed in a PyroMark MD™
System (Qiagen, Hilden, Germany) with the PyroGold
SQA™ Reagent Kit (Qiagen, Hilden, Germany) containing
nucleotides and prepared mixtures with enzymes or sub-
strates. For pyrogram exposure including CpG-site
methylation calculation, the Pyro Q-CpG™ Software
(Biotage, Uppsala, Sweden; Version 1.0.9.) was applied.
Only pyrograms including sharp peaks with satisfactory
heights for each injected nucleotide of interest and with-
out peaks for unsuccessful bisulfite treatment or back-
ground controls were considered.
Gene expression profiling analysis
Based on our previously published gene expression pro-
filing [23,24], we evaluated a 12p deletion associated
gene dosage effect of our own patients by comparing
complex karyotype cases with 12p13 deletion (n = 4) and
cases without (n = 28). In brief, normalized log2 trans-
formed gene expression levels of the minimally deletedregion were averaged and compared to the average un-
altered chromosome 12 regions.
SNP level3 datasets (archive: broad.mit.edu_LAML.Gen-
ome_Wide_SNP_6.Level_3.25.2004.0) and RNAseq level3
datasets (archive: bcgsc.ca_LAML.IlluminaGA_RNASeq.
Level_3.1.7.0) of AML patients were obtained from the
TCGA Research Network (http://cancergenome.nih.gov/).
Visualization and selection of the SNP data was done
using the Integrative Genomics Viewer [43,44]. The RPKM
values (RPKM= (10^9 * C)/(N * L); C =Number of reads
mapped to a gene, N =Total mapped reads in the experi-
ment, L = exon length in base-pairs for a gene) of the
corresponding gene-quantification files were extracted and
analyzed on gene level applying the t-test program of the
statistical program R, version 3.1.1 (http://www.R-project.
org/) [45]. Accordingly, box plots were made using the
boxplot function of R.Statistical analysis
We used the two-tailed Fisher’s exact test, Kruskal-
Wallis one-way analysis of variance, the unpaired t-test
and the ANOVA one-way analysis of variance. An effect
was considered significant if the p value was <0.05.Additional files
Additional file 1: Table S1. Karyotypes, genomic profiling, sequencing
results and methylation analyses of the patient cohort. Karyotypes of the
79 patients with CK-AML investigated in this study (classified according
to ISCN recommendations), results obtained by genomic profiling,
mutation analyses of ETV6 and CDKN1B (mutations are named according
to HGVS (http://www.hgvs.org/)), and mean methylation levels.
Additional file 2: Table S2. Overview of TP53 mutations. TP53 mutation
status of the 79 patients investigated in this study, mutations are named
according to HGVS (http://www.hgvs.org/). FISH results with a probe for
the locus 17p13 (TP53) are also shown if available.
Additional file 3: Table S3. Normalized log2 fluorescence ratio of six
CK-AML samples obtained from 2.8/8.0 k BAC/PAC arrays. Cut-off levels
for gains and losses were determined for each individual experiment.
After computing the ratios from dye-swap hybridization and subsequent
normalization, an individual set of balanced clones for each experiment
was used to calculate the mean and standard deviations. The cutoff levels
were defined as mean plus/minus three times the standard deviation.
Frequently affected regions recently detected as copy number polymor-
phisms (5q11, 7q22, 7q35, 14q32, and 15q11) were excluded from data
analysis.
Additional file 4: Table S4. List of GEO accession numbers. List of GEO
accession numbers for all samples run on the Agilent/Affymetrix platform.Abbreviations
AML: Acute myeloid leukemia; CK-AML: Acute myeloid leukemia with
complex karyotype; arrayCGH: Array comparative genomic hybridization;
HGVS: Humane Genome Variation Society; ISCN: International System for
Human Cytogenetic Nomenclature; MDS: Myelodysplastic syndrome; SNP
array: Single-nucleotide polymorphism array; TCGA: The cancer genome atlas.Competing interests
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